New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:11 EDTBDSIBioDelivery Sciences and Endo Pharmaceuticals report on BEMA Buprenorphine NDA
BioDelivery Sciences International announced that along with its commercial partner, Endo Pharmaceuticals, engaged in a positive pre-New Drug Application, or NDA, meeting with the FDA regarding BEMA Buprenorphine for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate. The positive outcome of the pre-NDA meeting allows BDSI and Endo to maintain expectations of an NDA filing with FDA for BEMA Buprenorphine in late 2014 or early 2015 as planned.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
10:01 EDTBDSIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:02 EDTBDSIBioDelivery Sciences downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use